prostate header graphic
Prostate Problem Guide

Prostate Cancer Stages In Simple Non-Medical Terms

It is extremely important that, following a diagnosis of prostate cancer, the stage and growth rate of the cancer is determined, so that the most suitable form of treatment can be given. This involves determining the spread of the cancer outside of the prostate gland and the manner in which the cancer is growing.

Prostate cancer cells are similar to other body cells in many ways and will go through various stages of growth and there are a number of tests and grading systems which can be used to determine and classify the stage of growth of prostate cancer cells.

A widely used method of grading is known as the Gleason system. In this case cancer cells are compared to normal cells and given a score to indicate their appearance when compared to normal cells. Grading runs from 1 to 5, with 1 representing a cell which is quite close to a normal cell and 5 indicating a cell which bears little resemblance to a normal cell.

Unfortunately cells in different areas of the prostate may be at different stages of development and so, in order to obtain an overall Gleason score, the scores are taken from the two areas which are most affected by cancer and the scores are then added together. This overall score, which will lie between 2 and 10, indicates an increasingly aggressive form of prostate cancer as the score increases.

A commonly used system in determining the extent to which cancer has spread is the TNM system, which uses a combination of the size of the tumor, the extent to which the lymph nodes have been affected and the presence of other related cancers appearing in sites other than the prostate gland.

Using the TNM system prostate cancer is then classified as being T1, T2, T3 or T4 cancer, with T1 and T2 indicating a cancer which is confined to the prostate gland and T3 and T4 indicating a cancer which has spread beyond the prostate gland.

Further information on prostate cancer stages:

Rather Than Just Beat Cancer, One Survivor Ambushed It - Patch.com


Rather Than Just Beat Cancer, One Survivor Ambushed It
Patch.com
Bill Jackson, a teacher at Menomonee Falls High School, survived prostate cancer with a proactive approach. Now, he's bringing his inspirational message to the American Cancer Society's Relay for Life event at the high school June 1.

Pfizer, Glaxo, J&J Grab ASCO Spotlight - TheStreet.com


TheStreet.com

Pfizer, Glaxo, J&J Grab ASCO Spotlight
TheStreet.com
ASCO officials also highlighted a mid-stage study of Johnson & Johnson's(JNJ) Zytiga in early-stage (pre-surgical) prostate cancer patients. Later during the ASCO meeting, which starts in two weeks, J&J will present new Zytiga results from a phase III ...
ASCO data to shine new light on Pfizer, Roche, J&J drugsFiercePharma

all 43 news articles »

Genomic Health Announces Presentation of Eighteen Studies Highlighting ... - MarketWatch (press release)


Genomic Health Announces Presentation of Eighteen Studies Highlighting ...
MarketWatch (press release)
REDWOOD CITY, Calif., May 16, 2012 /PRNewswire via COMTEX/ -- Genomic Health, Inc. (NASDAQ:GHDX) today announced that results from 18 separate studies covering breast, colon and prostate cancers will be presented at the American Society of Clinical ...

and more »